All reactions were carried out under a nitrogen atmosphere with anhydrous, commercial grade solvents, unless otherwise noted. All other reagents and solvents were reagent grade and used as received from commercial sources. Nuclear magnetic resonance (NMR) chemical shifts (δ) are reported in parts per million relative to internal tetramethylsilane (TMS). Yields refer to chromatographically and spectroscopically homogeneous materials, unless otherwise stated.
Hz, 1 H).
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C NMR (100 MHz, DMSO-d 6 ) δ ppm 21. 94, 42.80, 43.87, 68.17, 77.32, 97.66, 136.47, 143.87, 144.40, 154.29, 155.64 To a mixture of 4-(3-bromo-pyrazolo[1,5-a]pyrimidin-5-yl)-piperazine-1-carboxylic acid isopropyl ester (338.7 mg, 0.9 mmol), 2-methoxy-3-pyridineboronic acid (169.4 mg, 1.1 mmol), potassium phosphate tribasic monohydrate (423.9 mg, 1.84 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (78.6 mg, 0.1 mmol) contained in a 50 mL round-bottomed flask was added a solution of 30% (v/v) water in 1,2-dimethoxyethane (17 mL) and a magnetic stir bar. The reaction pot was fitted to a reflux condenser, lowered into an ambient temperature oil bath, and the system taken through 10 evacuation / N 2 blanket cycles while being rapidly stirred. The rapidly stirred, N 2 blanketed, reaction was heated to an oil bath temperature of 85 o C for 17 h then cooled and partitioned between brine (pH adjusted to 10 with 3N aqueous sodium hydroxide) and ethyl acetate. The separated organic layer was dried (MgSO 4 ) and evaporated to afford an oil which was purified by preparative reverse phase-HPLC to afford 76.0 mg of the titled compound as a free base. (dd, J=7.58, 2.02 Hz, 1 H).
C NMR (100 MHz, DMSO-d 6 ) δ ppm 21. 95, 42.85, 44.06, 53.10, 68.16, 97.21, 98.90, 116.40, 117.17, 134.55, 136.43, 141.99, 144.65, 144.71, 154.26, 155.46, 158.89 28.22, 28.45, 34.02, 35.07, 39.02, 39.97, 46.23, 47.06, 78.52, 78.87, 99.57, 113.35, 125.92, 130.80, 137.01, 154.37, 155.39 Compound BMT-124110 was prepared as described in WO Patent #038,112 (2015) , Example 45 (Vrudhula et al., 2015) . 
12.
[3H]-Tert-butyl (S)-2-(((3-(2-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl)amino)methyl)pyrrolidine-1-carboxylate was prepared as described in patent application WO 2013/134228 A1, Example 5.12.9 using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol as the coupling partner to obtain tert-butyl
yl)amino)methyl)pyrrolidine-1-carboxylate (2.0 mg, 4.88 mmol) and Cs 2 CO 3 (2.3 mg, mmol) in DMF (0.5 ml) was added [H-3]MeI (100 mCi). The reaction was stirred at ambient temperature for 1.5 hrs.
HPLC analysis showed one major peak corresponding to the product. The crude sample was purified by reverse phase HPLC (Luna 5u C18 (2) 
Baculovirus expression of recombinant protein kinases
Recombinant baculovirus encoding protein kinase domains were constructed using the Bac-to-Bac system from Invitrogen™ (ThermoFisher Scientific) and were used to infect suspension cultures of insect cells and express the recombinant proteins essentially as described previously (Kiefer et al., 2014) . The AAK1 (NCBI RefSeq accession NP_055726.3) kinase domain was expressed using a recombinant baculovirus vector encoding amino acids 9-330 fused behind glutathione S-transferase and an intervening Factor Xa cleavage site to produce GST-Xa-hAAK1(29-330). The amplified P2 virus was used to infect High Five™ (ThermoFisher Scientific) insect cells in suspension culture at 10.5 liter scale. The cells were harvested by sedimentation 62 h post-infection and yielded 329 grams of cell paste that was frozen at -80°C. Similarly, the GAK (NCBI RefSeq accession NP_005246.2) kinase domain was expressed using recombinant baculovirus encoding . The infected cells from 3.5 liters of suspension culture were harvested by sedimentation 65 h post-infection and yielded 68 grams of cell paste that was frozen. The kinase domain of BMP2K (NCBI RefSeq accession NP_942595.1) was expressed using recombinant baculovirus encoding GST-Xa-hBMP2K(1-367). The infected cells from 10 liters of suspension culture were harvested by sedimentation 52 h post-infection and yielded 120 grams of cell paste that was frozen.
inhibitors (from 2 µM to 33 pM). Compound stock solutions (10 mM) were prepared in DMSO. Kinase reactions were incubated at room temperature for 3 h and terminated by adding 60 ml of 35 mM EDTA buffer to each sample. Reaction solutions were analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product.
IC 50 values were derived by non-linear regression analysis of the concentration response data. The experimentally determined BIKE ATP Km value was 3.3 μM.
GAK radiometric kinase assay
Enzymatic activity of GAK was determined by phosphorylated product detection in a 33 P filter-binding assay using histone H1 protein (Millipore) as substrate. The assay mixture contained 100 nM recombinant GST-Xa-GAK (12-347) and 2 µM histone in a buffer containing 50 mM Tris, pH 7.5 containing 10 mM MgCl 2 , 2 mM DTT, and 0.5 mM EGTA. Compound stock solutions (10 mM) were prepared in DMSO and varying concentrations (from 100 µM to 1.7 nM) were added to the plate via ECHO acoustic transfer (Labcyte, Sunnyvale, CA). Reaction was initiated with the addition of 40 μM ATP (final) and [γ-33 P]-ATP to a final volume of 30 µl and quenched after 60 minutes with 30 µl 300 mM phosphoric acid. Sample was transferred to the phosphocellulose membrane filtration plate using a Biomek FX liquid handling station (Beckman Coulter), where it was subsequently aspirated and washed five times with 75 mM phosphoric acid. The plate was dried in a 65 °C oven for 10 minutes, the bottom was sealed and 20 µl Microscint-20 was added to the plate. The plate was then read on a Topcount plate reader (Perkin Elmer, Waltham, MA). The experimentally determined GAK ATP Km value was 52 μM.
AMBIT /DiscoveRx Kinome Scan
Dry test compounds were provided to AMBIT/DiscoveRx for evaluation in their KINOMEscan panel.
Compounds were resuspended and diluted in DMSO prior to inclusion in the assay at a final concentration of 1 μM. The ability of test compound to compete with proprietary ATP binding site probes was evaluated for 389 kinases (Davis et al., 2011) . Inhibition of probe binding was expressed as % control binding.
AAK1 radioligand binding assay
C57Bl6 mouse brains were homogenized in ice cold hypotonic lysis buffer (10 mM Tris buffer pH7.4 with 5 mM EDTA and 1 μl/ml Sigma protease inhibitor cocktail) using a polytron. The homogenate was centrifuged at 32000xg for 20 minutes and the resulting pullet was resuspended in homogenate wash buffer (50 mM Tris buffer pH 7.4 with 5 mM EDTA and 1 μl/ml Sigma protease inhibitor) and centrifuged again at 32000xg for 20 minutes. The resulting pellets were resuspended in assay buffer (120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , and 50 mM Tris buffer (pH 7.4)) and frozen in aliquots at a protein concentration of 2.5 mg/ml and stored at -70 °C until use. Test compounds were evaluated for their ability to displace the AAK1 ATP binding site inhibitor 3H-LP-927443 (AAK1 Kd=467±56 pM (data not shown), specific activity 83.1 Ci/mmol) from mouse brain membrane homogenates. Non-specific binding was defined using an AAK1 inhibitor from a different chemotype BMS-901715 (AAK1 IC 50 =200 pM). Competition binding assays were carried out in 96 well plates at room temperature. All reagents were prepared in assay buffer. The radioligand was diluted in assay buffer containing 1% BSA. Briefly 2 μl of test compound (11 point dose response curves) or non specific inhibitor control (final concentration 1 μM) were added to the plate, followed by 20 μl of 
AAK1 Cellular Assay
HEK293F cells were cultured in media containing DMEM (Gibco, cat. #11965), 10% FBS (SAFC Biosciences, cat. #12103C), 1X GPS (glutamine, penicillin and streptomycin). On day one, 12 million cells were plated on a 10 cm dish at ~80% confluent. On day two, each 10 cm dish was transfected with 48 μg DNA (3 μg AAK1/HA/pIRES (full length human, NCBI accession no. NP_055726.2), 45 µg Flag/AP2MI/pcDNA (full length human, NCBI accession no. NM_004068.3), 144 μl Lipofectamine 2000 (Invitrogen, cat.# 11668-019), and 1.5 ml OPTI-MEM per manufacturer's instructions. On day three, cells were resuspended, pelleted by centrifugation at 1000 rpm for 5 min, and resuspended in 2.75 ml DMEM + 0.5% FBS. An aliquot of cells (100 μl) was transferred to each well in a 96 well plate.
Compounds were dissolved in DMSO and diluted in DMSO to 1000 times the final concentration.
Compound solutions (1 μl) were then mixed in 500 µl DMEM + 0.5% FBS and 100 µl of diluted compound were added to each well. Plates were then incubated at 37 °C and 5% CO 2 for 3 h. Cells were then resuspended and pelleted in a tube. For Western Blot analysis, cell pellets were resuspend in 40 μl 1X LDS-PAGE sample buffer (Invitrogen, cat.# NP0008) + 2X Halt phosphatase and protease inhibitor cocktail (Thermo Scientific, cat.#1861284), followed by sonication with microtip sonicator set at 5 for 8-10 seconds. Five μl of 10X NuPage Sample Reducing Agent (with 50 mM DTT) was to each sample followed by heat denaturing at 70 °C for 10 min. Each sample (10 µl) was loaded on a 4-20% TrisGlycine Criterion 26-well gel (Biorad, cat.# 345-0034) for the phospho-µ2 blot and 10 µl per lane in a 4-12% Bis-Tris (+MES buffer) NuPAGE 26-well gel (Invitrogen, cat.# WG1403BX10) for the µ2 blot. For controls, 2 ng of phospho-µ2 or 20 ng µ2/Flag proteins were loaded on each gel. After SDS-PAGE, samples were transferred to PVDF membrane and membranes were blocked for one hour in TBST + 5% milk, followed by wash 3X for 5-10 min with TBST. Membranes were probed with rabbit anti-phospho-µ2 (1:5000; a rabbit polyclonal antibody produced by New England Peptide and affinity purified at Lexicon) in TBST + 5% BSA. NuPAGE gels were probed with mouse anti-Flag (1:500; Sigma, cat.# F1804) in TBST + 5% milk, and these primary antibodies were incubated overnight at 4 °C on a rocker.
On day four, Western blots were washed 3X for 5-10 minutes with TBST, probe with anti-rabbit-HRP (1:2000; BioRad, cat.# 170-6515) or anti-mouse-HRP (1:2000; Biorad, cat.# 170-6516) in TBST + 5% milk for 1 hour at RT, washed 3X for 10 minutes with TBST, and developed with ECL reagent (GE Healthcare, cat.# RPN2132) on a Versadoc. Images were captured with a camera and percent inhibition was calculated for each sample by first normalizing to total µ2 expression levels and then comparing to 0% and 100% controls. IC 50 values were then calculated using Excel fitting software. 
SNL model
Mechanical allodynia after SNL surgery for wild-type (n=8-11) and BIKE knock out mice (n=12-16).
BIKE knockout mice develop only 70% of the mechanical allodynia response in observed wt controls. ***p<0.001 using 2-way RMANOVA with Bonferroni post-hoc WT vs. BIKE KO mice. 
. Pharmacokinetics of LP-935509 in mice
Four mice were dosed with LP-935509 either intravenously (1 mg/kg) or orally (10 mg/kg). Blood samples were taken over a 24 hour period and LP-935509 plasma levels were determined. Data were fit to standard PK models. LP-935509 had ~100% oral bioavailability and had a plasma t 1/2 of 3.6 hr. The Cmax for the 10 mg/kg oral dose was 5.2 µM at 0.5 hours post dose. 
. Pharmacokinetics of LP-935509 in rats
Three rats were dosed either intravenously (2 mg/kg) or orally (10 mg/kg). Blood samples were taken at 10 timepoints over a 24 hour period and LP-935509 plasma levels were determined. Data were fit to standard PK models. LP-935509 had 50% oral bioavailability and a plasma t 1/2 of 4 hr. The Cmax for the Tables   Supplemental Table 1 Mouse SNL ( 
